Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Transcode Therapeutics Inc
RNAZCurrent price
0.35 USD
+0.05 USD (+16.74%)
Last closed
0.29 USD
Company
www.transcodetherapeutics.com
ISIN
US89357L1052
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
4 473 542 USD
Yield for 12 month
-98.33 %
1Y
3Y
5Y
10Y
15Y
RNAZ
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts. Address: 6 Liberty Square, Boston, MA, United States, 02109
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
120 USDP/E ratio
0.001Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
+753 146 USD
Current Year
-516 746 USD
Last Year
-98 606 USD
Current Quarter
-142 835 USD
Last Quarter
-141 647 USD
Key Figures RNAZ
1 year
3 years
5 years
10 years
EBITDA
-17 683 348 USD
Operating Margin TTM
PE Ratio
0.001
Return On Assets TTM
-207.95 %
PEG Ratio
–
Return On Equity TTM
-1048.7 %
Wall Street Target Price
120 USD
Revenue TTM
–
Book Value
0.18 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
268.14 USD
Diluted Eps TTM
268.14 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics RNAZ
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RNAZ
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:40
Payout Ratio
–
Last Split Date
16.01.2024
Dividend Date
–
Stock Valuation RNAZ
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
0.001
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-0.5934
Price Book MRQ
3.3832
Financials RNAZ
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RNAZ
For 52 weeks
0.22 USD
128 USD
50 Day MA
0.41 USD
Shares Short Prior Month
175 766
200 Day MA
1.77 USD
Short Ratio
0.37
Shares Short
278 561
Short Percent
1.61 %
BeatStart